Immutep reaches mid-point in global trial

Company News

by Rachael Jones

Biotechnology company Immutep (ASX:IMM) has reached the mid-point in patient enrolment for its ongoing AIPAC Phase IIb clinical trial evaluating eftilagimod alpha in combination with paclitaxel in metastatic breast cancer.

In 2018 clinical trial sites were opened in Germany, the UK, France and Hungary complementing the existing active sites in Belgium, Poland and the Netherlands, thereby leading to an acceleration of the monthly recruitment rate.

All clinical sites are now actively recruiting and treating patients as part of the randomised and controlled phase of the study.

The primary clinical end-point of the study is Progression-Free Survival.

From a commercial perspective, there is a great deal of interest from patients, clinicians, and investors in the LAG-3 immune control mechanism.

Shares in Immutep (ASX:IMM) are trading flat at 3c.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.